HENRY BERNARD LOWMAN
Pilots in El Granada, CA
License number
California A2567655
Issued Date
Apr 2016
Expiration Date
Apr 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
PO Box 2556, El Granada, CA 94018
Professional information
Therapeutic Compositions Comprising Anti-Ige Antibodies And Immunosuppressive Agent
US Patent:
6723833, Apr 20, 2004
Filed:
Nov 17, 2000
Appl. No.:
09/716028
Inventors:
Henry B. Lowman - El Granada CA
Leonard G. Presta - San Francisco CA
Paula M. Jardieu - San Mateo CA
John Lowe - Daly City CA
Leonard G. Presta - San Francisco CA
Paula M. Jardieu - San Mateo CA
John Lowe - Daly City CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C07K 1600
US Classification:
53038873, 5303873, 5362523, 536 2353, 435 696
Abstract:
The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
Igf-I Variants
US Patent:
6506874, Jan 14, 2003
Filed:
Nov 28, 2000
Appl. No.:
09/723981
Inventors:
Yves Dubaquie - San Francisco CA
Henry Lowman - El Granada CA
Henry Lowman - El Granada CA
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 3828
US Classification:
530303, 530300, 530350, 514 3, 435 691
Abstract:
IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
Anti-Jagged 1/Jagged 2 Cross-Reactive Antibodies, Activatable Anti-Jagged Antibodies And Methods Of Use Thereof
US Patent:
2014001, Jan 9, 2014
Filed:
Jun 21, 2013
Appl. No.:
13/923935
Inventors:
Jason Gary Sagert - San Mateo CA, US
Paul H. Bessette - Camarillo CA, US
Henry Bernard Lowman - El Granada CA, US
Nancy E. Stagliano - San Francisco CA, US
Olga Vasiljeva - Cupertino CA, US
Paul H. Bessette - Camarillo CA, US
Henry Bernard Lowman - El Granada CA, US
Nancy E. Stagliano - San Francisco CA, US
Olga Vasiljeva - Cupertino CA, US
International Classification:
C07K 16/18
US Classification:
4241341, 53038815, 5303919, 5303915, 4241421, 5303873, 536 2353, 4353201, 536 234, 435 696
Abstract:
This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Antibody Variants With Faster Antigen Association Rates
US Patent:
2010029, Nov 18, 2010
Filed:
Oct 19, 2009
Appl. No.:
12/581574
Inventors:
Henry B. Lowman - El Granada CA, US
Jonathan S. Marvin - New York NY, US
Jonathan S. Marvin - New York NY, US
International Classification:
A61K 39/395, C12P 21/08, C12P 21/06, C07H 21/04, C12N 15/63, C12N 5/10, G01N 33/566
US Classification:
4241331, 5303873, 435 696, 536 2353, 4353201, 435328, 436501
Abstract:
Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds.
Method Of Producing Antibodies With Improved Function
US Patent:
2009020, Aug 20, 2009
Filed:
Jun 5, 2006
Appl. No.:
11/447506
Inventors:
John C. Joly - San Mateo CA, US
Henry B. Lowman - El Granada CA, US
Domingos Ng - San Francisco CA, US
Amy Y. Shen - San Mateo CA, US
Bradley R. Snedecor - Portola Valley CA, US
Henry B. Lowman - El Granada CA, US
Domingos Ng - San Francisco CA, US
Amy Y. Shen - San Mateo CA, US
Bradley R. Snedecor - Portola Valley CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, C12P 21/00, C12N 5/10, A61P 35/00
US Classification:
4241341, 435 696, 435325
Abstract:
The invention provides methods for controlling fucosylation levels and improving ADCC activity in antibodies.
Anti-Vegf Antibodies
US Patent:
2007019, Aug 23, 2007
Filed:
Nov 16, 2006
Appl. No.:
11/560524
Inventors:
Manuel Baca - Ivanhoe, AU
James Wells - Burlingame CA, US
Leonard Presta - San Francisco CA, US
Henry Lowman - El Granada CA, US
Yvonne Chen - San Mateo CA, US
James Wells - Burlingame CA, US
Leonard Presta - San Francisco CA, US
Henry Lowman - El Granada CA, US
Yvonne Chen - San Mateo CA, US
International Classification:
A61K 39/395, C07K 16/22
US Classification:
424145100, 530388250
Abstract:
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
Insulin-Like Growth Factor Agonist Molecules
US Patent:
6251865, Jun 26, 2001
Filed:
Mar 31, 1998
Appl. No.:
9/052888
Inventors:
Ross G. Clark - Auckland, NZ
Henry B. Lowman - El Granada CA
Iain C. A. F. Robinson - St. Albans, GB
Henry B. Lowman - El Granada CA
Iain C. A. F. Robinson - St. Albans, GB
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 3808, A61K 3810, C07K 706, C07K 708, C07H 2104
US Classification:
514 15
Abstract:
Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.
Antibody Variants
US Patent:
2009001, Jan 8, 2009
Filed:
Sep 28, 2006
Appl. No.:
11/536109
Inventors:
Yvonne M. Chen - San Mateo CA, US
Henry B. Lowman - El Granada CA, US
Yves Muller - Zepernick, DE
Henry B. Lowman - El Granada CA, US
Yves Muller - Zepernick, DE
International Classification:
A61K 39/395, C07K 16/18, C07K 1/00, C12N 15/11, C12N 15/00, C12N 5/06, C12P 21/04, A61P 43/00
US Classification:
4241331, 5303873, 530402, 536 2353, 4353201, 435325, 435 696
Abstract:
Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.
Antibody Variants
US Patent:
2007028, Dec 6, 2007
Filed:
Oct 24, 2006
Appl. No.:
11/552445
Inventors:
Yvonne Chen - San Mateo CA, US
Henry Lowman - El Granada CA, US
Yves Muller - Zepernick, DE
Henry Lowman - El Granada CA, US
Yves Muller - Zepernick, DE
International Classification:
A61K 39/395, C07K 16/18, C12N 15/13, C12N 15/81, C12N 15/85, C12N 5/10, C12P 21/00
US Classification:
424133100, 435320100, 435325000, 435358000, 435069600, 530387300, 536023530
Abstract:
Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.
Antibody Variants
US Patent:
2004008, May 6, 2004
Filed:
Jul 21, 2003
Appl. No.:
10/624153
Inventors:
Yvonne Chen - San Mateo CA, US
Henry Lowman - El Granada CA, US
Yves Muller - Zepemick, DE
Henry Lowman - El Granada CA, US
Yves Muller - Zepemick, DE
Assignee:
Genentech, Inc.
International Classification:
A61K039/395, C07K016/18
US Classification:
424/130100, 530/387300
Abstract:
Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.